What is the annual revenue of Cytokinetics?
Diodes Incorporated records annual revenues scaling between USD 1.3 billion and USD 1.6 billion, positioning the company as a leading global manufacturer and supplier of high-quality discrete, analog, and semiconductor products. Serving diverse markets such as communications, computing, consumer electronics, industrial automation, and automotive electronics, the firm's revenue architecture reflects broad geographical distribution and specialized product innovation. Financial performance indicators are tied to global semiconductor cycle dynamics, fab utilization rates, inventory normalization trends across supply chains, and continuous R&D expansion into advanced power management technologies.
Related FAQs
Securities or corporate entities trading under ticker abbreviations similar to CELC are evaluated by financial professionals on a case-by-case basis depending on their specific industry sector, such as biotechnology or specialized technology.
Cytokinetics is a specialty cardiovascular biopharmaceutical company focused on pioneering scientific innovations in muscle biology and developing potential new medicines for patients suffering from diseases of cardiac muscle dysfunction.
Aficamten (marketed under brand names such as Myqorzo) has been authorized as a once-daily oral cardiac myosin inhibitor designed to treat symptomatic obstructive hypertrophic cardiomyopathy.
Cytokinetics has developed key cardiovascular drug candidates, notably aficamten (marketed under the brand name MYQORZO), which is a cardiac myosin inhibitor designed for the treatment of adults with symptomatic obstructive hypertrophic cardiomyop...
Cytokinetics, Incorporated officially completed its initial public offering and began trading its common stock on the NASDAQ stock exchange under the ticker symbol CYTK on April 29, 2004.
No, Cytokinetics (CYTK) does not pay dividends. As a growth-focused biotechnology company, it prioritizes the reinvestment of all available capital into its research, development, and commercialization efforts.
Assessing whether Celsius Holdings shares are undervalued requires analyzing standard valuation multiples—such as price-to-earnings and price-to-sales ratios—relative to its historical growth rates and projected future earnings.
The professional analyst consensus for Cytokinetics is a "Strong Buy," with virtually all covering analysts recommending that investors buy or hold the stock rather than sell.
Wall Street equity research analysts covering Cytokinetics, Incorporated (CYTK) establish a consensus 12-month average price target of approximately $99.37 to $105.00 per share.
Cytokinetics is widely considered a promising player in the biotechnology sector, garnering strong positive sentiment from market analysts who view its future prospects favorably.
As of July 2026, the overwhelming consensus rating for Cytokinetics is a "Buy," with a significant percentage of analysts classifying it as a "Strong Buy".
Yes, Dominion Energy (D) pays a quarterly dividend to its shareholders.
Cytokinetics is a late-stage biopharmaceutical enterprise dedicated to discovering, developing, and commercializing muscle biology-directed medicines for treating serious cardiovascular and neuromuscular diseases.
Dacotah Bank is an established regional financial institution headquartered in Aberdeen, South Dakota, maintaining total consolidated assets exceeding $3.1 billion.
Cytokinetics, Incorporated (NASDAQ: CYTK) trades at $76.45 per share, supported by a robust market capitalization exceeding $10.3 billion.